GT Biopharma

GT Biopharma EPS

The Earnings per Share (EPS) of GT Biopharma (GTBP) as of Nov 22, 2026 is -128.59 USD. In the previous year, Earnings per Share (EPS) was -173.41 USD — a change of -25.85% (higher).

EPS

-128.59USD

YoY

-25.85%

Last updated:

Earnings per Share (EPS) of GT Biopharma is 2025 -128.59 USD. Earnings per Share (EPS) of GT Biopharma was 2024 -173.41 USD. It decreases by -25.85% higher compared to the previous year.

The GT Biopharma EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2022
-441.52 USD
Jan 1, 2023
-137.63 USD
Jan 1, 2024
-173.41 USD
Jan 1, 2025
-128.59 USD
Jan 1, 2026 (e)
-10.75 USD
Jan 1, 2027 (e)
-8.00 USD
Jan 1, 2029 (e)
0.25 USD
Jan 1, 2030 (e)
7.50 USD
The GT Biopharma EPS history
YEAREPSYoY
est7.50USD+2,900.00%
est0.25USD-103.13%
est-8.00USD-25.58%
est-10.75USD-91.64%
-128.59USD-25.85%
-173.41USD+26.00%
-137.63USD-68.83%
-441.52USD+163.33%
-167.67USD+2,991.98%
-5.42USD-97.69%
-234.37USD-89.13%
-2,156.29USD+76.34%
-1,222.83USD-106.26%
19,536.00USD-409.50%
-6,312.06USD+403.96%
-1,252.50USD-90.31%
-12,927.50USD-30.12%
-18,500.00USD-2,456.69%
785.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GT Biopharma Stock analysis

What does GT Biopharma do? GT Biopharma Inc, based in Brisbane, California, is a clinical-stage biopharmaceutical company operating in the Health Care sector. The company focuses on developing immuno-oncology therapeutics using its proprietary TriKE NK cell engager platform, which enhances natural killer cells to target cancer. It employs two full-time staff and is listed on the stock market since October 22, 2013. Its lead product, GTB-3550, is a tri-specific fusion protein for CD33-expressing cancers, currently in Phase 1 clinical trials. GT Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GT Biopharma stock

Earnings per Share (EPS) of GT Biopharma is -128.59 USD in 2025.

Earnings per Share (EPS) of GT Biopharma changed from -173.41 USD to -128.59 USD, representing a -25.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) GT Biopharma since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — GT Biopharma

All Key Metrics — GT Biopharma